EMERYVILLE, Calif., March 27, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, non-antibiotic, anti-infective Aganocide® compounds for the topical non-systemic treatment and prevention of infections, today reported full-year and fourth quarter financial results for 2011.
